Advertisement

U.S. markets open in 6 hours 55 minutes

S&P Futures
4,569.25
+11.25(+0.25%)
Dow Futures
35,654.00
+34.00(+0.10%)
Nasdaq Futures
15,581.75
+86.00(+0.55%)
Russell 2000 Futures
2,315.40
+5.10(+0.22%)
Crude Oil
83.61
-0.15(-0.18%)
Gold
1,806.80
0.00(0.00%)

Advertisement

Takeda Pharmaceutical Company Limited (TAK)

NYSE - NYSE Delayed Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

14.03-0.04 (-0.28%)

At close: 4:00PM EDT

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

Engulfing Line (Bullish)

View all chart patterns

Performance Outlook

Previous Close	14.07
Open	14.07
Bid	0.00 x 3100
Ask	0.00 x 4000
Day's Range	13.94 - 14.07
52 Week Range	13.91 - 19.97
Volume	1,734,183
Avg. Volume	2,202,146

Market Cap	44.125B
Beta (5Y Monthly)	1.10
PE Ratio (TTM)	11.64
EPS (TTM)	1.21
Earnings Date	N/A
Forward Dividend & Yield	0.84 (5.95%)
Ex-Dividend Date	Mar 30, 2021
1y Target Est	20.37

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Undervalued

93% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for TAK

Learn more

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

Takeda Pharmaceutical Company L
Analyst Report: Roche Holding AGRoche is a Swiss biopharmaceutical and diagnostic company. The firm's best-selling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 60% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
Rating
Fair Value
Economic Moat
6 days agoMorningstar

All

News

Press Releases

Research Reports

Benzinga
Wave Life Sciences, Takeda Discontinue Research On Preclinical CNS Programs
Wave Life Sciences Ltd (NASDAQ: WVE) has amended its ongoing collaboration with Takeda Pharmaceutical Company Limited (NYSE: TAK) to discontinue discovery & research of preclinical programs for central nervous system (CNS) indications over a four-year research term. Under terms of the amendment, Takeda will pay Wave $22.5 million for collaboration-related research and preclinical expenses. The amendment allows Wave to advance or partner CNS programs, including those using ADAR editing, outside o
Benzinga
Calithera Buys Two Oncology Candidates From Takeda For $45M
Calithera Biosciences Inc (NASDAQ: CALA) has agreed to acquire two clinical-stage cancer-focused compounds from Takeda Pharmaceutical Company Limited (NYSE: TAK). The transaction terms include a total upfront cash payment to Takeda of $10 million and $35 million in Calithera Series A preferred stock. Additionally, Takeda will be eligible to receive milestone payments across both programs. Calithera will pay tiered royalties of high single-digits to low teens on future net sales. The first compou
Zacks
Seagen's (SGEN) Cancer Portfolio Strong, Stiff Rivalry a Worry
Seagen (SGEN) focuses on improving sales of its marketed drugs that are approved for different types of cancer indications. Stiff competition in the target market remains a woe.